DXFD-1通过准NF-κB和Nrf2信号传导来缓解DSS诱导的性结肠炎
Sai Li1, Xinyu Fu1, Cheng Cheng1
1Nanjing Drum Tower Hospital Life and Health Research Center, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China.
International immunopharmacology
|December 5, 2025
概括
一种新型化合物DXFD-1显示出治疗性结肠炎 (UC) 的前景. 它通过调节关键信号通路来减少炎症和氧化应激,为UC患者提供潜在的新治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的肠道疾病,具有复杂的发病因子.
- 目前的UC治疗有局限性和不良影响,需要新的治疗药物.
- 在UC发育过程中,NF-κB和Nrf2信号通路至关重要.
研究的目的:
- 为了研究DXFD-1的治疗作用,一种新的硫化释放化合物,在性结肠炎上.
- 阐明DXFD-1作用的基本机制,重点关注NF-κB和Nrf2信号传递.
主要方法:
- 在体外:用脂聚糖 (LPS) 刺激的RAW264.7细胞来建模炎症.
- 在体内:硫酸德克斯 (DSS) 诱导UC的小鼠模型.
- 评估了氧化应激标志物 (ROS,MDA,SOD,GSH-PX) 和炎症类细胞因子 (TNF-α,IL-6,IL-1β).
主要成果:
- DXFD-1通过激活Nrf2信号和增加抗氧化酶 (SOD,GSH-PX) 来抑制氧化应激.
- DXFD-1降低了活性氧物种 (ROS),髓氧化酶 (MPO) 和恶性甲酸 (MDA) 的水平.
- DXFD-1显著降低了NF-κB信号的调节,减少了促炎性细胞因子 (TNF-α,IL-6,IL-1β).
结论:
- 在UC模型中,DXFD-1显示出强大的抗炎和抗氧化应激特性.
- 该化合物的机制涉及抑制NF-κB和激活Nrf2信号通路.
- DXFD-1有可能成为未来UC治疗临床开发的领先化合物.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.4K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.4K


